Vor Biopharma Inc. filings document a clinical-stage biotechnology issuer focused on telitacicept and autoimmune disease development. The record includes Form 8-K disclosures for operating and financial results, Regulation FD presentations, clinical and regulatory updates, material agreements, governance changes and capital-structure matters.
Proxy materials describe director elections, equity incentive plan matters, auditor ratification and annual-meeting voting procedures. Other filings address executive compensation arrangements, Nasdaq-listed common stock, a reverse stock split, equity plan share adjustments and security-holder rights tied to the company’s common stock and outstanding awards.
Vor Biopharma Inc. received an initial insider ownership report from TCG Crossover investment entities. The filing shows indirect holdings of 2,836,539 shares of Vor Biopharma common stock as of March 30, 2026, with TCG Crossover funds and their general partners reported as ten percent owners sharing voting, investment, and dispositive power.
RA Capital Management and affiliates filed Amendment No. 13 to update their ownership in Vor Biopharma Inc. They report beneficial ownership of 12,187,524 shares of common stock, representing 19.9% of the class, calculated on 54,185,582 shares outstanding as of March 30, 2026.
The change reflects an increase in Vor Biopharma’s outstanding shares rather than new purchases or sales by the reporting persons. The position includes common stock, common stock warrants for up to 1,056,072 shares, pre-funded warrants for up to 10,000,000 shares, and stock options held for the benefit of RA Capital, all subject to beneficial ownership blockers that limit exercise above specified ownership caps.
Vor Biopharma Inc. is repositioning itself as an autoimmune-focused biopharmaceutical company centered on telitacicept, a BAFF/APRIL‑targeting fusion protein in-licensed from RemeGen in June 2025. Telitacicept is already approved in China for SLE, RA and gMG, with additional Biologics License Applications pending for Sjögren’s disease and IgA nephropathy.
The company now leads global Phase 3 trials in generalized myasthenia gravis and Sjögren’s disease to support potential approvals in the United States, Europe and Japan, leveraging extensive Chinese Phase 3 data showing durable efficacy and a favorable safety profile. Earlier oncology and cell therapy programs, including trem-cel and VCAR33, have been discontinued and related intellectual property sold.
Under the telitacicept license, Vor paid a $125 million upfront (including a warrant for 16,000,000 shares) and owes up to $330 million in regulatory and $3.775 billion in sales milestones, plus tiered royalties. In March 2026 it agreed to a $75.0 million private placement of 5,338,078 shares at $14.05 per share with TCGX affiliates, and has granted registration rights for resale. A 1‑for‑20 reverse stock split was effected in September 2025, and 48,847,504 common shares were outstanding as of March 23, 2026.
Vor Biopharma Inc. is repositioning itself as an autoimmune-focused biopharmaceutical company centered on telitacicept, a BAFF/APRIL‑targeting fusion protein in-licensed from RemeGen in June 2025. Telitacicept is already approved in China for SLE, RA and gMG, with additional Biologics License Applications pending for Sjögren’s disease and IgA nephropathy.
The company now leads global Phase 3 trials in generalized myasthenia gravis and Sjögren’s disease to support potential approvals in the United States, Europe and Japan, leveraging extensive Chinese Phase 3 data showing durable efficacy and a favorable safety profile. Earlier oncology and cell therapy programs, including trem-cel and VCAR33, have been discontinued and related intellectual property sold.
Under the telitacicept license, Vor paid a $125 million upfront (including a warrant for 16,000,000 shares) and owes up to $330 million in regulatory and $3.775 billion in sales milestones, plus tiered royalties. In March 2026 it agreed to a $75.0 million private placement of 5,338,078 shares at $14.05 per share with TCGX affiliates, and has granted registration rights for resale. A 1‑for‑20 reverse stock split was effected in September 2025, and 48,847,504 common shares were outstanding as of March 23, 2026.
Vor Biopharma Inc. entered into a securities purchase agreement with entities affiliated with TCGX for a private placement of 5,338,078 common shares at $14.05 per share, for gross proceeds of about $75.0 million. The closing is expected on or about March 30, 2026, subject to customary conditions.
After closing, Vor expects to have 54,185,582 common shares outstanding. The company plans to use the net proceeds to advance its clinical pipeline, including telitacicept programs, and for general corporate purposes. No placement agent was used. Vor also granted investors registration rights and will file a Form S-3 to register the resale of the new shares.
Vor Biopharma Inc. attracted a larger disclosed stake from RA Capital-affiliated investors through a change in warrant terms. RA Capital Management, its healthcare fund, and managers Peter Kolchinsky and Rajeev Shah now report beneficial ownership of 9,023,068 shares of common stock, representing 19.9% of the class based on 41,519,840 shares outstanding as of January 26, 2026. The increase stems from a March 12, 2026 notice raising the Pre-Funded Warrants’ maximum ownership percentage from 9.99% to 19.99%, which caused an additional 3,611,297 warrant shares to be counted as beneficially owned, effective March 13, 2026. The filing also notes ownership through common shares, common stock warrants, and stock options held for RA Capital’s benefit.
Vor Biopharma Inc. received an amended Schedule 13G from Verve Capital Limited, a Samoa-organized entity, reporting a significant passive stake. Verve Capital beneficially owns 4,297,464 shares of common stock through pre-funded warrants, subject to a 9.99% ownership blocker.
The 9.99% beneficial ownership is calculated using 38,720,196 shares of common stock outstanding as of December 18, 2025, plus 4,297,464 shares issuable upon exercise of the pre-funded warrants. Verve Capital certifies the holding is not for the purpose of changing or influencing control of Vor Biopharma.
Vor Biopharma Inc. large holder disclosure: A group of Venrock Healthcare Capital entities and individuals Nimish Shah and Bong Koh report beneficial ownership of 2,216,075 shares of Vor Biopharma common stock as of December 31, 2025, representing 9.99% of the company.
The position includes common shares and Pre-Funded Warrants held across VHCP III, VHCP Co-Investment III and VHCP EG, all subject to a 9.99% beneficial ownership blocker that limits warrant exercise. The percentage is calculated using 21,910,630 shares outstanding as of November 19, 2025 plus 272,309 shares issuable upon warrant exercise.
Vor Biopharma Inc. received an updated ownership filing from Great Point Partners and related individuals. The group reports beneficial ownership of 1,370,107 shares of Vor Biopharma common stock, representing 3.30% of the outstanding shares.
Great Point Partners, Dr. Jeffrey R. Jay and Ms. Lillian Nordahl report shared voting and shared dispositive power over all 1,370,107 shares, with no sole voting or dispositive power. The percentage is based on 41,519,840 shares outstanding as reported in Vor Biopharma’s Form S-3 on January 29, 2026. The filers certify the shares are held on a passive basis and represent ownership of 5 percent or less of the class.
VOR Biopharma Inc. received an updated ownership report from Paradigm BioCapital entities and related persons on an amended Schedule 13G. Paradigm BioCapital Advisors LP, its general partner, Senai Asefaw, M.D., and Paradigm BioCapital International Fund Ltd. together report beneficial ownership of 1,750,000 shares of VOR Biopharma common stock.
This stake represents 4.5% of the outstanding common stock, based on 38,720,196 sharesDecember 31, 2025. The Paradigm BioCapital International Fund Ltd. itself directly holds 1,546,061 shares, or 4.0% of the class. The reporting group certifies that the securities were not acquired to change or influence control of VOR Biopharma.
Qiming-affiliated investment entities filed an amended Schedule 13G reporting their passive ownership in Vor Biopharma Inc.’s common stock. Qiming Venture Partners VIII-HC, L.P. and Qiming GP VIII-HC, LLC each report beneficial ownership of 1,089,767 shares, representing 2.8% of the common stock outstanding as of December 31, 2025. Qiming Venture Partners VIII Investments, LLC and Qiming GP VIII, LLC each report beneficial ownership of 910,172 shares, representing 2.4% of the same share class. All reporting persons certify the holdings were not acquired to change or influence control of Vor Biopharma.